This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.

Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332

There are currently 24 open trials. In 107 locations

What is a Clinical Trial?

Step 3: View Details

Trial Title:

MUK eleven

Treatments:

Reolysin® (Pelareorep)
Lenalidomide (Revlimid)
Pomalidomide (Imnovid®)

Myeloma stage:

Relapsed, Refractory

Trial phase:

I

Summary

Summary:

This trial is investigating whether Reolysin, a type of viral therapy, can halt relapse in patients who are being treated with lenalidomide (Revlimid®) or pomalidomide (Imnovid®). It is specifically looking to identify the best dose of Reolysin to use.

Locations

Locations:

St James' Hospital, Leeds

Who can enter the study?

Who can enter the study?:

  • Patients who are on currently being treated with lenalidomide or pomalidomide (with or without steroids) but who are showing signs of relapse
  • Patients cannot enter if they have non-secretory myeloma i.e. do not produce paraproteins or free light chains
What's involved?

What's involved?:

Depending on their current treatment, patients will continue to receive either lenalidomide (10mg dose or current dose if lower than 10mg) or pomalidomide (1mg or current dose if lower than 1mg) on days 1-21 of a 28 day cycle. Patients who are also on steroid treatment must stop taking it at least 48 hours before starting their first Reolysin treatment.

Reolysin is given as a one hour intravenous (into the vein) infusion on days 1, 8, 15 and 22.

Treatment is continued until there are signs the myeloma is progressing or because of other reasons.

Patients are required to visit the outpatient clinic for regular blood test and checkups.

Clinical Information

Clinical Information
(for Medical Professionals):

This trial is aiming to determine the maximum tolerated dose of Reolysin that can be given in combination with lenalidomide or pomalidomide in two separate cohorts of relapsed and/or refractory myeloma patients. It is also investigating the safety, side-effects and effectiveness of the treatment combinations.

For more information, click here.

 

Do you want to talk to someone? Call our myeloma Infoline